Search

Your search keyword '"Van Voorhis, Wesley C."' showing total 1,068 results

Search Constraints

Start Over You searched for: Author "Van Voorhis, Wesley C." Remove constraint Author: "Van Voorhis, Wesley C."
1,068 results on '"Van Voorhis, Wesley C."'

Search Results

1. Exquisite selectivity of griselimycin extends to beta subunit of DNA polymerases from Gram-negative bacterial pathogens

2. Identification of and Structural Insights into Hit Compounds Targeting N‑Myristoyltransferase for Cryptosporidium Drug Development

4. Rapid Epidemic Expansion of Chikungunya Virus East/Central/ South African Lineage, Paraguay

6. Increased interregional virus exchange and nucleotide diversity outline the expansion of chikungunya virus in Brazil

8. Accurate de novo design of membrane-traversing macrocycles

9. Structures of Trichomonas vaginalis macrophage migratory inhibitory factor.

10. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage

11. A short-term treatment with BKI-1294 does not protect foetuses from sheep experimentally infected with Neospora caninum tachyzoites during pregnancy

12. Endochin-like quinolones (ELQs) and bumped kinase inhibitors (BKIs): Synergistic and additive effects of combined treatments against Neospora caninum infection in vitro and in vivo

13. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

14. In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts

15. One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases

16. Unraveling the Complexity of Chikungunya Virus Infection Immunological and Genetic Insights in Acute and Chronic Patients.

18. Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice

19. Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned

21. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.

23. Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis

24. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

25. Efficacy of the bumped kinase inhibitor BKI-1708 against the cyst-forming apicomplexan parasites Toxoplasma gondii and Neospora caninum in vitro and in experimentally infected mice

28. In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19

31. A comparative study of eight serological methods shows that spike protein-based ELISAs are the most accurate tests for serodiagnosing SARS-CoV-2 infections in cats and dogs

32. Clofazimine pharmacokinetics in HIV‐infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics

33. Crystal structures of NAD(P)H nitroreductases from Klebsiella pneumoniae.

34. Rapid Discovery of Antimicrobial and Antimalarial Agents from Natural Product Fragments.

35. Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites

36. Chemical genetics of Plasmodium falciparum

38. Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy

39. An early treatment with BKI-1748 exhibits full protection against abortion and congenital infection in sheep experimentally infected with Toxoplasma gondii

40. Shotgun Kinetic Target-Guided Synthesis Approach Enables the Discovery of Small-Molecule Inhibitors against Pathogenic Free-Living Amoeba Glucokinases

41. Characterization of a family I inorganic pyrophosphatase from Legionella pneumophila Philadelphia 1

43. Rapid Epidemic Expansion of Chikungunya Virus East/Central/South African Lineage, Paraguay

45. Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis

48. Molecular Targets of the 5-Amido-Carboxamide Bumped Kinase Inhibitor BKI-1748 in Cryptosporidium parvum and HCT-8 Host Cells.

Catalog

Books, media, physical & digital resources